# 3D-Bioprinting: Gewebeimplantate aus dem Drucker – Alexander Leutner (Cellbricks Therapeutics)

Page: https://stenobird.com/podcast/startup-insider-6744721/3d-bioprinting-gewebeimplantate-aus-dem-drucker-alexander-leutner-cellbricks-therapeutics
Text version: https://stenobird.com/podcast/startup-insider-6744721/3d-bioprinting-gewebeimplantate-aus-dem-drucker-alexander-leutner-cellbricks-therapeutics.md
Podcast: [Startup Insider](https://stenobird.com/podcast/startup-insider-6744721)
Published: 2026-04-29T11:00:00+00:00
Episode link: https://startup-insider.com/alle-podcast-folgen/
Audio file: https://afp-912057-injected.calisto.simplecastaudio.com/d2790bdf-c937-4878-8f59-941f6b6b4ef5/episodes/fa45544e-fe04-41c7-b524-6739ba00fcd0/audio/128/default.mp3?aid=rss_feed&awCollectionId=d2790bdf-c937-4878-8f59-941f6b6b4ef5&awEpisodeId=fa45544e-fe04-41c7-b524-6739ba00fcd0&feed=ZQdsoEnZ
Processing state: processed
JSON: https://stenobird.com/v1/public/podcasts/startup-insider-6744721/episodes/3d-bioprinting-gewebeimplantate-aus-dem-drucker-alexander-leutner-cellbricks-therapeutics
Duration seconds: 1964

## Resource

Cellbricks Therapeutics is developing a 3D-bioprinting platform to manufacture functional human tissue implants. The company aims to progress from wound healing applications to complex organ replacement through strategic pharmaceutical partnerships.

## Highlights
- Main idea: Cellbricks utilizes a light-based bioprinting process to stabilize cells within a hydrogel structure
- Practical takeaway: The platform model allows for scalable applications ranging from wound healing to breast reconstruction and organ replacement
- Business model: The company pursues co-development deals with large pharma to leverage massive upfront and milestone payments
- Failure mode: High R&D costs and the intense regulatory requirements of the biotech sector necessitate significant capital and strategic partnerships
- Strategic vision: Using a platform approach enables the company to launch multiple assets and diversify therapeutic use cases

## Topics

3D-Bioprinting, Regenerative Medicine, Deep Tech, Biotechnology, Tissue Engineering, Pharmaceutical Partnerships, Medical Innovation, Berlin Startups

## Chapters
- 1:00 — Introduction to Cellbricks: An introduction to Alexander Leutner and the moonshot vision of biofabricated human tissue implants.
- 3:40 — The Roadmap to Organ Replacement: Discussing the transition from simpler tissue manufacturing to the ultimate goal of complex organ replacement.
- 8:50 — The Bioprinting Process: Technical details on using light to cure functionalized biomaterials into a cell-embedded hydrogel.
- 16:50 — Platform Assets and Use Cases: How the technology scales from wound healing to advanced tissue reconstruction and dual-use defense applications.
- 19:20 — The Pharma Partnership Model: Analyzing the economics of co-development deals, milestone payments, and the symbiosis between startups and Big Pharma.
- 22:00 — Scaling and Fundraising: Insights into managing growth, securing venture capital, and navigating the deep-tech funding landscape in Germany.
- 32:30 — Impact and Future Outlook: The broader implications of bioprinting for the deep-tech ecosystem, investors, and the global medical community.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/startup-insider-6744721/episodes/3d-bioprinting-gewebeimplantate-aus-dem-drucker-alexander-leutner-cellbricks-therapeutics/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/startup-insider-6744721/3d-bioprinting-gewebeimplantate-aus-dem-drucker-alexander-leutner-cellbricks-therapeutics.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.